MONTRÉAL, Nov. 23, 2012 /CNW/ - Aptilon Corporation ("Aptilon" or the
"Corporation") (TSXV: APZ) today announced that its wholly-owned
subsidiary, Aptilon Holdings Inc. ("Holdings"), has concluded the sale
of substantially all of its assets related to its business of providing
multichannel, e-detailing and physician marketing services to members
of the healthcare industry (the "Business") to Indegene Aptilon, Inc.
("Indegene"), an entity dealing at arm's length with Aptilon and
The sale of these assets will allow Aptilon to focus its activities on
the healthcare marketing services it acquired in September 2009. The
Board of Directors of Aptilon remains the same after this transaction,
and it is comprised of: Justin Beckett, Mark Benthin, André Brosseau,
Roger Korman and Denis Martineau.
The Corporation also announces that it has reached agreements with its
Canadian lenders regarding the repayment of its long-term debt. The
revised payment schedule coincides with the earnout payments that may
be received from Indegene in June 2013 and June 2014 pursuant to the
Asset Purchase Agreement. In addition, the loan granted by FIER
CPVC-Montreal has been reimbursed in full.
The Corporation anticipates being able to file the missing annual and
quarterly financial statements with the regulatory authorities by the
end of this year, and it understands that the current cease-trade
orders should be lifted shortly after the filings. The Corporation
anticipates being in a position to hold its annual meeting of
shareholders by the end of February 2013.
About Aptilon Corporation
Aptilon enables pharmaceutical, biotech and medical device companies to
effectively reach, message, connect and interact with US physicians and
healthcare professionals via multiple access channels. Its innovative
service offerings provide targeted impressions and interactions
through: video and mobile detailing, digital access channels and
permission-based email services. Top pharmaceutical companies and
respected healthcare organizations have adopted Aptilon's solutions to
market to, engage and interact with leading healthcare practitioners.
For more information, visit www.aptilon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as such term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Aptilon Corporation
For further information: